Your browser doesn't support javascript.
loading
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Lawrenson, Kate; Kar, Siddhartha; McCue, Karen; Kuchenbaeker, Karoline; Michailidou, Kyriaki; Tyrer, Jonathan; Beesley, Jonathan; Ramus, Susan J; Li, Qiyuan; Delgado, Melissa K; Lee, Janet M; Aittomäki, Kristiina; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Arun, Banu K; Arver, Brita; Bandera, Elisa V; Barile, Monica; Barkardottir, Rosa B; Barrowdale, Daniel; Beckmann, Matthias W; Benitez, Javier; Berchuck, Andrew; Bisogna, Maria; Bjorge, Line; Blomqvist, Carl; Blot, William; Bogdanova, Natalia; Bojesen, Anders; Bojesen, Stig E; Bolla, Manjeet K; Bonanni, Bernardo; Børresen-Dale, Anne-Lise; Brauch, Hiltrud; Brennan, Paul; Brenner, Hermann; Bruinsma, Fiona; Brunet, Joan; Buhari, Shaik Ahmad; Burwinkel, Barbara; Butzow, Ralf; Buys, Saundra S; Cai, Qiuyin; Caldes, Trinidad; Campbell, Ian; Canniotto, Rikki; Chang-Claude, Jenny; Chiquette, Jocelyne; Choi, Ji-Yeob.
Afiliação
  • Lawrenson K; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
  • Kar S; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • McCue K; QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.
  • Kuchenbaeker K; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Michailidou K; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Tyrer J; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Beesley J; QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.
  • Ramus SJ; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
  • Li Q; Medical College, Xiamen University, Xiamen 361102, China.
  • Delgado MK; Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Lee JM; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
  • Aittomäki K; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
  • Andrulis IL; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki 00029 HUS, Finland.
  • Anton-Culver H; Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada.
  • Arndt V; Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
  • Arun BK; Department of Epidemiology, Genetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, California 92697, USA.
  • Arver B; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
  • Bandera EV; University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • Barile M; Department of Oncology, Karolinska University Hospital, Stockholm 171 77, Sweden.
  • Barkardottir RB; Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA.
  • Barrowdale D; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan 20141, Italy.
  • Beckmann MW; Department of Pathology, Landspitali University Hospital and BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik 600169-2039, Iceland.
  • Benitez J; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Berchuck A; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen 91054, Germany.
  • Bisogna M; Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid E-28029, Spain.
  • Bjorge L; Centro de Investigación en Red de Enfermedades Raras, Valencia 28029, Spain.
  • Blomqvist C; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA.
  • Blot W; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York 10065, USA.
  • Bogdanova N; Department of Gynecology and Obstetrics, Haukeland University Hospital, 5021 Bergen, Norway.
  • Bojesen A; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, N-5020 Bergen, Norway.
  • Bojesen SE; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki FIN-00029, Finland.
  • Bolla MK; Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA.
  • Bonanni B; International Epidemiology Institute, Rockville, Maryland 20850, USA.
  • Børresen-Dale AL; Gynaecology Research Unit, Hannover Medical School, Hannover D-30625, Germany.
  • Brauch H; Department of Clinical Genetics, Vejle Hospital, Vejle 7100, Denmark.
  • Brennan P; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
  • Brenner H; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev 2730, Denmark.
  • Bruinsma F; Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev 2730, Denmark.
  • Brunet J; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge CB1 8RN, UK.
  • Buhari SA; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan 20141, Italy.
  • Burwinkel B; Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo N-0310, Norway.
  • Butzow R; K.G. Jebsen Center for Breast Cancer Research, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo N-0310, Norway.
  • Buys SS; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart D-70376, Germany.
  • Cai Q; University of Tübingen, Tübingen 72074, Germany.
  • Caldes T; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Campbell I; International Agency for Research on Cancer, Lyon 69008, France.
  • Canniotto R; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
  • Chang-Claude J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
  • Chiquette J; Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg 69121, Germany.
  • Choi JY; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004, Australia.
Nat Commun ; 7: 12675, 2016 09 07.
Article em En | MEDLINE | ID: mdl-27601076
ABSTRACT
A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10(-20)), ER-negative BC (P=1.1 × 10(-13)), BRCA1-associated BC (P=7.7 × 10(-16)) and triple negative BC (P-diff=2 × 10(-5)). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10(-3)) and ABHD8 (P<2 × 10(-3)). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3'-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cromossomos Humanos Par 19 / Neoplasias da Mama / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Alelos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Cromossomos Humanos Par 19 / Neoplasias da Mama / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Alelos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Nat Commun Ano de publicação: 2016 Tipo de documento: Article